Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622016 | 0.88 | EPHX2 (0.58) | EPHX1HSD11B1CACNA1HEPHX2KDM4E | |
| SCHEMBL3620654 | 0.78 | HSD11B1 (0.60) | HSD11B1EPHX2ALDH1A1 | |
| SCHEMBL4741319 | 0.78 | ALDH1A1 (0.45) | EPHX1CACNA1HEPHX2KDM4EALDH1A1 | |
| SCHEMBL3617709 | 0.78 | ALDH1A1 (0.45) | EPHX1CACNA1HEPHX2KDM4EALDH1A1 | |
| SCHEMBL3620629 | 0.78 | ALDH1A1 (0.45) | EPHX1CACNA1HEPHX2KDM4EALDH1A1 | |
| SCHEMBL16395729 | 0.76 | EPHX2 (0.50) | EPHX1CACNA1HEPHX2KDM4EALDH1A1 | |
| SCHEMBL3625180 | 0.73 | ALDH1A1 (0.51) | EPHX1HSD11B1CACNA1HEPHX2KDM4E | |
| SCHEMBL14595385 | 0.72 | HSD11B1 (0.47) | HSD11B1KDM4EALDH1A1 | |
| SCHEMBL3623689 | 0.72 | HSD11B1 (0.61) | EPHX1HSD11B1CACNA1HEPHX2 | |
| SCHEMBL13002272 | 0.72 | HDAC3 (0.57) | EPHX1CACNA1HEPHX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | claimed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | claimed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | claimed |
| EP-2094263-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2009-09-02 | — | — | EP | claimed |
| WO-2008074384-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2008-06-26 | — | — | WO | claimed |
| EP-1935420-A1 | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-06-25 | — | — | EP | claimed |
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2094263-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074384-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1935420-A1 | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, CYP11B1 | EPHX1 492/4885HSD11B1 1/4885CACNA1H 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.